R_5 is selected from the group consisting of H, an oxygen protecting group, and



, wherein "〰" indicates appoint of attachment;

R_{6a} is optionally substituted C_{1-10} alkyl;

R_{6b} is H, C_{1-10} alkyl, C_{1-10} hydroxyalkyl, allyl, haloalkyl, aryl, heteroalkenyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

R_{8a} and R_{8b} are each independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl;

R_{9a} is selected from the group consisting of H, optionally substituted C_{1-10} alkyl, hydroxyalkyl, optionally substituted C_{1-10} alkylene-$NR_TR_{T'}$, optionally substituted C_{1-10} alkylene-cycloalkyl-$NR_TR_{T'}$, and optionally substituted alkoxyalkyl; wherein R_T and $R_{T'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, and optionally substituted C_{1-10} alkylene-heterocycloalkyl;

R_{10b} is selected from the group consisting of H, optionally substituted C_{1-10} alkyl, and optionally substituted C_{1-10} alkoxy; and

R_{10a} is selected from the group consisting of -CO_2H, –CO_2-optionally substituted alkyl, –CON($R_{z'}$)($R_{z''}$), optionally substituted C_{1-10} alkylene-R_{101}, optionally substituted C_{2-10} alkenylene-R_{101}, and optionally substituted C_{2-10} alkynylene-R_{101}; wherein:

R_{101} is selected from the group consisting of (C_{1-6} alkyl)-S-, (C_{1-6} alkyl)-SO-, (C_{1-6} alkyl)-SO_2-, -OH, optionally substituted -O-(C_{1-6} alkyl), -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein:

$R_{z'}$ and $R_{z''}$ are each independently H or optionally substituted alkyl;

R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$), wherein $R_{y'}$ and $R_{y''}$ are each independently H or optionally substituted alkyl; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein

each R_y is independently selected from the group consisting of -H and optionally substituted C_{1-10} alkyl; and

R_{11a} and R_{11b} are each independently selected from the group consisting of -H and optionally substituted C_{1-10} alkyl.

[0005b] In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0005c] In another aspect of the present disclosure, there is provided a kit comprising a compound disclosed herein, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition also disclosed herein, and instructions for administering to a subject in need thereof.

[0005d] In a further aspect of the present disclosure, there is provided a use of a compound of disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition also disclosed herein, in the manufacture of a medicament for treating an infectious disease in a subject in need thereof.

[0005e] In another aspect of the present disclosure, there is provided a compound disclosed herein, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition also disclosed herein, for use in the treatment of an infectious disease in a subject in need thereof.

[0005f] In a further aspect of the present disclosure, there is provided a compound which is selected from:

Compound #	**Structure**
2	

Compound #	Structure
3	
4	
5	
6	

Compound #	Structure
7	
8	
9	
10	

Compound #	Structure
11	
12	
13	
15	
16	

Compound #	Structure
17	
18	
19	
20	
21	

Compound #	Structure
168	
193	
200	
201	
202	

Compound #	Structure
203	
204	
212	
221	
223	

Compound #	Structure
224	
225	
228	
229	
231	

Compound #	Structure
233	
234	
235	
236	

Compound #	Structure
237	
238	
239	 and
240	 ;

or a pharmaceutically acceptable salt thereof.

[0005g] In another aspect of the present disclosure, there is provided a compound which is selected from:

Compound #	Structure
1	
22	
23	
24	
25	

Compound #	Structure
26	
27	
28	
29	
35	

Compound #	Structure
36	
37	
38	
39	

Compound #	Structure
40	
41	
42	
44	

Compound #	Structure
45	
46	
47	
48	

Compound #	Structure
49	
50	
51	
52	
53	

Compound #	Structure
54	
55	
56	
57	
58	

Compound #	Structure
59	
60	
61	
62	
63	

Compound #	Structure
64	
65	
66	
67	

Compound #	Structure
68	
69	
70	
71	

Compound #	Structure
72	
73	
74	
75	
76	

Compound #	Structure
77	
78	
79	
80	
81	

Compound #	Structure
82	
83	
84	
85	
86	

Compound #	Structure
87	
88	
89	
90	
91	
92	

Compound #	Structure
93	
94	
95	
96	

Compound #	Structure
97	
98	
99	
101	
102	

Compound #	Structure
103	
104	
105	
106	
107	

Compound #	Structure
108	
109	
110	
111	
112	

Compound #	Structure
113	
114	
115	
116	
117	

Compound #	Structure
118	
119	
121	
122	
123	

Compound #	Structure
124	
125	
127	
128	
129	

Compound #	Structure
130	
131	
132	
133	
134	

Compound #	Structure
135	
136	
137	
138	
139	

Compound #	Structure
140	
142	
144	
146	
147	
148	

Compound #	Structure
149	
150	
151	
153	
154	

Compound #	Structure
155	
156	
157	
158	
159	
160	

Compound #	Structure
161	
162	
163	
164	

Compound #	Structure
165	
166	
169	
170	

Compound #	Structure
171	
172	
173	
174	

Compound #	Structure
175	
176	
178	
180	
181	

Compound #	Structure
189	
190	
192	

Compound #	Structure
194	
195	
196	

Compound #	Structure
197	
198	
199	
205	

Compound #	Structure
208	
209	
216	
217	
218	
219	

Compound #	Structure
220	
227	
230	
232	 and
233	 ;

or a pharmaceutically acceptable salt thereof.

[0005h] In a further aspect of the present disclosure, there is provided a compound which is selected from:

Compound #	Structure
112	
120	
126	
141	
143	

Compound #	Structure
145	
152	
177	
182	 and
226	 ;

or a pharmaceutically acceptable salt thereof.

[0006] Disclosed herein are compounds that are novel, synthetically accessible 13-membered macrolides. The compounds are novel antibiotics with unexpectedly potent antimicrobial activity.

[0007] In one example, the present disclosure provides compounds of Formula (**I**):



I

or a pharmaceutically acceptable salt thereof, wherein:

one of R_{2a} and R_{2b} is selected from the group consisting of H, halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and

the other of R_{2a} and R_{2b} is selected from the group consisting of halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, substituted amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

CLAIMS

1. A compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

one of R_{2a} and R_{2b} is selected from the group consisting of H, halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl; and

the other of R_{2a} and R_{2b} is selected from the group consisting of halo, optionally substituted C_{1-10} alkyl, optionally substituted C_{1-10} alkoxy, and optionally substituted C_{1-10} alkenyl, wherein C_{1-10} alkyl, C_{1-10} alkoxy, and C_{1-10} alkenyl are optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, substituted amino, alkyl, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

each of R_{4a} and R_{4b} is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl;

R_5 is selected from the group consisting of H, an oxygen protecting group, and



, wherein "〰" indicates appoint of attachment;

R_{6a} is optionally substituted C_{1-10} alkyl;

R_{6b} is H, C_{1-10} alkyl, C_{1-10} hydroxyalkyl, allyl, haloalkyl, aryl, heteroalkenyl, heterocycloalkyl, or heteroaryl, any of which can be optionally substituted with one or more groups selected from the group consisting of halo, aryl, amino, heteroalkyl, heteroalkenyl, heterocycloalkyl, and heteroaryl;

R_{8a} and R_{8b} are each independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl;

R_{9a} is selected from the group consisting of H, optionally substituted C_{1-10} alkyl, hydroxyalkyl, optionally substituted C_{1-10} alkylene-$NR_TR_{T'}$, optionally substituted C_{1-10} alkylene-cycloalkyl-$NR_TR_{T'}$, and optionally substituted alkoxyalkyl; wherein R_T and $R_{T'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, and optionally substituted C_{1-10} alkylene-heterocycloalkyl;

R_{10b} is selected from the group consisting of H, optionally substituted C_{1-10} alkyl, and optionally substituted C_{1-10} alkoxy; and

R_{10a} is selected from the group consisting of -CO_2H, –CO_2-optionally substituted alkyl, –$CON(R_{z'})(R_{z''})$, optionally substituted C_{1-10} alkylene-R_{101}, optionally substituted C_{2-10} alkenylene-R_{101}, and optionally substituted C_{2-10} alkynylene-R_{101}; wherein:

R_{101} is selected from the group consisting of (C_{1-6} alkyl)-S-, (C_{1-6} alkyl)-SO-, (C_{1-6} alkyl)-SO_2-, -OH, optionally substituted -O-(C_{1-6} alkyl), -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein:

$R_{z'}$ and $R_{z''}$ are each independently H or optionally substituted alkyl;

R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$, wherein $R_{y'}$ and $R_{y''}$ are each independently H or optionally substituted alkyl; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein

each R_y is independently selected from the group consisting of -H and optionally substituted C_{1-10} alkyl; and

R_{11a} and R_{11b} are each independently selected from the group consisting of -H and optionally substituted C_{1-10} alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula IG:



IG.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R_{9a} is -H or C_{1-4} alkyl.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R_{11a} and R_{11b} are each methyl.

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein one of R_{2a} and R_{2b} is optionally substituted C_{1-10} alkyl.

6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein one of R_{2a} and R_{2b} is methyl and the other is halo.

7. The compound of claim 3, or a pharmaceutically acceptable salt thereof, which is a compound of formula IH:



IH.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, which is a compound of formula IIA, IIB, IIC, or IID:



IIA;



IIB;



IIC;



IID;

R_{10b} is selected from the group consisting of H and optionally substituted $C_{1\text{-}10}$ alkyl; and

R_{10a} is selected from the group consisting of -CO_2H, –CO_2-optionally substituted alkyl, –CON($R_{z'}$)($R_{z''}$), and optionally substituted C_{1}-$_{10}$ alkylene-$R_{101,}$ C_{2}-$_{10}$ alkenylene-$R_{101,}$ and C_{2}-$_{10}$ alkynylene-$R_{101;}$ wherein

R_{101} is selected from the group consisting of ($C_{1\text{-}6}$ alkyl)-S-, ($C_{1\text{-}6}$ alkyl)-SO-, ($C_{1\text{-}6}$ alkyl)-SO_2-, -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_x and $R_{x'}$ are each independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$); or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein:

each R_y is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R_{9a} is –H, methyl, ethyl, propyl, isopropyl, butyl, or isobutyl.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is selected from the group consisting of optionally substituted C_{1-10} alkylene-R_{101}, C_{2-10} alkenylene-R_{101}, and C_{2-10} alkynylene-R_{101}; wherein:

R_{101} is selected from the group consisting of -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R_{101} is selected from the group consisting H, -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_x and $R_{x'}$ are each independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein:

each R_y is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl; and

R_{10b} is selected from the group consisting of H and optionally substituted C_{1-10} alkyl.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is -C_1-C_{10} alkylene-R_{101a};

R_{101a} is selected from the group consisting of (C_{1-6} alkyl)-S-, (C_{1-6} alkyl)-SO-, (C_{1-6} alkyl)-SO_2-, -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted

heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted hydroxyalkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$); or R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein each R_y is independently selected from the group consisting of -H and optionally substituted $C_{1\text{-}10}$ alkyl.

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof,

wherein R_{10a} is selected from the group consisting of:  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .

 ,  ,  ,  , and

 ;

wherein

$NR_xR_{x'}$ is selected from the group consisting of -N(Me)(Et), -N(Me)$_2$, -N(Me)(t-Bu), -N(Me)(iPr), -NH(Me), -NH(iPr), -N(Et)$_2$, -N(Me)(cyclopropyl), -NH(cyclopropyl), -N(Me)(cyclobutyl), -NH(cyclobutyl), -N(Me)(cyclopentyl), -NH(cyclopentyl), -N(Me)(cyclohexyl), and -NH(cyclohexyl);

$MeSCH_2CH_2$-, $MeSOCH_2CH_2$-, $MeSO_2CH_2CH_2$-,  , and

 , and wherein "∿∿∿" indicates a point of attachment.

13. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted R_{101a2}-CH_2-, R_{101a2}-CH(OH)-, R_{101a2}-CH(OMe)-,

 , or R_{101a2}-C(=O)-, wherein "∿∿∿" indicates a point of attachment; and

R_{101a2} is selected from the group consisting of -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein R_x and $R_{x'}$ are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-N($R_{y'}$)($R_{y''}$); or R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and whereineach R_y is independently selected from the group consisting of H and optionally substituted C_{1-10} alkyl.

14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein: R_{101a2}-CH_2- is -CH_2NHMe, -$CH_2N(Me)_2$, -CH_2N(Me)(cyclopropyl), -CH_2NH(oxetanyl), -CH_2NHCH_2(cyclopropyl), or  , wherein " ~~~ " indicates a point of attachment.

15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein: R_{10a} is R_{101a2}-CH_2-; and

R_{101a2} is selected from the group consisting of optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.

16. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is an optionally substituted R_{101a2}-CH_2-, R_{101a2}-CH(OH)-, R_{101a2}-CH(OMe)-,  , or R_{101a2}-C(=O)-, wherein " ~~~ " indicates a point of attachment; and R_{101a2} is an optionally substituted piperidinyl selected from the group consisting of  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  .


























, and , wherein "" indicates a point of attachment.

17. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted R_{101a2}-CH_2-, R_{101a2}-CH(OH)-, R_{101a2}-CH(OMe)-,

 , or R_{101a2}-C(=O)-, wherein "" indicates a point of attachment; and

R_{101a2} is an optionally substituted  selected from the group consisting of








 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  , and  ,

wherein "〰" indicates a point of attachment.

18. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein: R_{10a} is an optionally substituted R_{101a3}-CH_2-, R_{101a3}-CH(OH)-, R_{101a3}-CH(OMe)-,

 , or R_{101a3}-C(=O)-, wherein "〰" indicates a point of attachment; and R_{101a3} is an optionally substituted heteroaryl.

19. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein: R_{10a} is an optionally substituted R_{101a4}-CH_2-, R_{101a4}-CH(OH)-, R_{101a4}-CH(OMe)-,

 , or R_{101a4}-C(=O)-, wherein "〰" indicates a point of attachment; and R_{101a4} is an optionally substituted azetidinyl.

20. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein: R_{10a} is an optionally substituted azetidinyl-CH_2- selected from the group consisting of

 and  , wherein "〰" indicates a point of attachment.

21. The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted R_{101a5}-CH_2-, R_{101a5}-CH(OH)-, R_{101a5}-CH(OMe)-,



, or R_{101a5}-C(=O)-, wherein "〰" indicates a point of attachment; and

R_{101a5} is an optionally substituted cyclobutyl.

22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein:

R_{101}-CH_2- is an optionally substituted cyclobutyl selected from the group consisting of



,



,



, and



,

wherein "〰" indicates a point of attachment.

23. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R_{10a} is an optionally substituted $C_{2\text{-}10}$ alkenylene-R_{101};

R_{101} is selected from the group consisting of -OH, -O-alkyl, -$NR_xR_{x'}$, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; wherein

R_x and $R_{x'}$ are each independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocycloalkyl, optionally substituted alkylene-aryl, optionally substituted alkylene-heteroaryl, -C(=O)-alkyl, and -C(=O)-alkylene-$N(R_{y'})(R_{y''})$; or

R_x and $R_{x'}$ together with the atom to which they are attached form an optionally substituted 3-, 4-, 5-, 6-, or 7-membered ring optionally containing an additional heteroatom selected from the group consisting of O, S, SO, SO_2, NR_y, and N-C_1-C_{10} alkyl; and wherein

each R_y is independently selected from the group consisting of -H and optionally substituted $C_{1\text{-}10}$ alkyl.

24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is an optionally substituted C_{2-5} alkenylene-R_{101} selected from the group consisting of  ,  ,  ,  , and  .

25. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein R_{10a} is an optionally substituted alkenylene-R_{101} which is  , wherein A is an optionally substituted cycloalkyl or heterocycloalkyl and R_{101e} is selected from the group consisting of -H, alkyl, and -$NR_xR_{x'}$, wherein R_x and $R_{x'}$ are each independently selected from the group consisting of -H and optionally substituted alkyl, and wherein "〰" indicates a point of attachment.

26. A compound which is selected from:

Compound #	Structure
2	
3	

Compound #	Structure
4	
5	
6	
7	
8	

Compound #	Structure
9	
10	
11	
12	
13	

Compound #	Structure
15	
16	
17	
18	
19	

Compound #	Structure
20	
21	
168	
193	
200	

Compound #	Structure
201	
202	
203	
204	
212	

Compound #	Structure
221	
223	
224	
225	
228	

Compound #	Structure
229	
231	
233	
234	
235	

Compound #	Structure
236	
237	
238	
239	 and

Compound #	Structure
240	 ;

or a pharmaceutically acceptable salt thereof.

27. A compound which is selected from:

Compound #	Structure
1	
22	
23	

Compound #	Structure
24	
25	
26	
27	
28	

Compound #	Structure
29	
35	
36	
37	

Compound #	Structure
38	
39	
40	
41	
42	

Compound #	Structure
44	
45	
46	
47	

Compound #	Structure
48	
49	
50	
51	
52	

Compound #	Structure
53	
54	
55	
56	
57	

Compound #	Structure
58	
59	
60	
61	
62	

Compound #	Structure
63	
64	
65	
66	
67	

Compound #	Structure
68	
69	
70	
71	

Compound #	Structure
72	
73	
74	
75	
76	

Compound #	Structure
77	
78	
79	
80	
81	

Compound #	Structure
82	
83	
84	
85	
86	
87	

Compound #	Structure
88	
89	
90	
91	
92	
93	

Compound #	Structure
94	
95	
96	
97	
98	

Compound #	Structure
99	
101	
102	
103	
104	

Compound #	Structure
105	
106	
107	
108	
109	

Compound #	Structure
110	
111	
112	
113	
114	
115	

Compound #	Structure
116	
117	
118	
119	
121	
122	

Compound #	Structure
123	
124	
125	
127	
128	
129	

Compound #	Structure
130	
131	
132	
133	
134	
135	

Compound #	Structure
136	
137	
138	
139	
140	

Compound #	Structure
142	
144	
146	
147	
148	
149	

Compound #	Structure
150	
151	
153	
154	
155	

Compound #	Structure
156	
157	
158	
159	
160	
161	

Compound #	Structure
162	
163	
164	
165	

Compound #	Structure
166	
169	
170	
171	

Compound #	Structure
172	
173	
174	
175	
176	

Compound #	Structure
178	
180	
181	
189	
190	

Compound #	Structure
192	
194	
195	

Compound #	Structure
196	
197	
198	

Compound #	Structure
199	
205	
208	
209	
216	

Compound #	Structure
217	
218	
219	
220	
227	
230	

Compound #	Structure
232	 and
233	 ;

or a pharmaceutically acceptable salt thereof.

28. A compound which is selected from:

Compound #	Structure
112	
120	

Compound #	Structure
126	
141	
143	
145	
152	
177	

Compound #	Structure
182	 and
226	 ;

or a pharmaceutically acceptable salt thereof.

29. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

30. A kit comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29, and instructions for administering to a subject in need thereof.

31. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29, in the manufacture of a medicament for treating an infectious disease in a subject in need thereof.

32. The use of claim 31, wherein the infectious disease is a gram-negative or gram-positive bacterial infection or a parasitic infection.

33. A compound of claim 1, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 29, for use in the treatment of an infectious disease in a subject in need thereof.

34. The compound or pharmaceutical composition for use of claim 33, wherein the infectious disease is a gram-positive or gram-negative bacterial infection or a parasitic infection.